-

Closed Loop Medicine Appoints Konstantinos Vlassis as Chief Technology Officer

Key executive leadership role will oversee design and implementation of technology strategy, engineering resources and infrastructure to deliver corporate objectives

LONDON--(BUSINESS WIRE)--Closed Loop Medicine Ltd., a leading TechBio company developing combination prescription drug plus software therapy products that enable personalized dose optimization, today announced that it has appointed Konstantinos Vlassis as Chief Technology Officer (CTO). Bringing extensive expertise in designing and implementing technology strategies to support product delivery, Konstantinos will oversee the management of the Company’s technology platforms and will have responsibility for engineering, information security and technology infrastructure.

Konstantinos is an experienced technology leader with more than 20 years of experience in building high performance agile teams. As CTO, he will play a pivotal role in leading Closed Loop Medicine’s Engineering Team and facilitating cross-functional collaboration. Konstantinos will be a key member of the Executive Leadership Team working to meet short- and long-term business goals and growth.

During his career, Konstantinos created scalable high-transaction platforms, re-architected legacy applications to Service Oriented Architecture and refactored solutions from different programming languages to deliver B2B and B2C products in healthcare, market research and data companies.

In his previous role, Konstantinos was CTO at Medis Medical Imaging, where he established a full agile continuous integration and delivery process, while initiating a major digital transformation of the company’s products incorporating AI/ML tools. During that time, Konstantinos secured the acquisition of AMID, a software-as-a-medical-device company, and launched the first Medis product incorporating the acquired technology. Prior to this, Konstantinos was the interim CTO at Winnow Systems Ltd, during which time he led the development and successful release of the award-winning AI product Winnow Vision which has been widely used in the hospitality industry. Konstantinos holds an MBA from Cass Business School, and MSc Information Systems from Brunel University.

Konstantinos Vlassis, CTO of Closed Loop Medicine, commented: I am thrilled to be joining Closed Loop Medicine and becoming an integral part of the development of our technology platform and overall software engineering, information security, and infrastructure to support bringing these life-changing products to the market. I am excited to work closely with the product, regulatory and operational teams to leverage the capabilities of our ground-breaking technologies that have the potential to revolutionize disease management and improve health outcomes for millions of patients.”

Dr. Hakim Yadi PhD OBE, CEO & Co-Founder of Closed Loop Medicine, said: “It has been a pivotal year for the Company’s growth, particularly to establish strategic collaborations and strengthen our senior leadership team. As Chief Technology Officer, Konstantinos brings a wealth of experience in designing and implementing productive, transparent, accountable technology strategies within strict regulatory constraints and delivering innovative products. As we continue to develop our dose optimization combination products enabling bespoke treatment decisions at an individual patient level, the expertise Konstantinos brings to the team is invaluable and I’m delighted to welcome him to the team.”

For more information visit: www.closedloopmedicine.com

Contacts

Closed Loop Medicine


Release Versions

Contacts

Social Media Profiles
More News From Closed Loop Medicine

Closed Loop Medicine Launches First Personalized GLP-1 Dosing Platform in U.S.

LONDON--(BUSINESS WIRE)--Closed Loop Medicine Ltd (CLM), a leader in personalized pharmaceutical dosing, today announced the U.S. launch of WeDosify, which enables clinicians to personalize GLP-1 titration at scale. The launch comes as the global anti-obesity market, valued at over $30 billion in 2024, is projected to reach $100 billion by 2030. Despite this growth, GLP-1 therapies face a major real-world challenge: up to 44% of patients discontinue treatment within six months, with that figure...

US Patent Office Grants Closed Loop Medicine Key Patents for Cardiometabolic Capabilities in GLP-1 and Direct Oral Anti-Coagulants (DOAC) Therapies

LONDON--(BUSINESS WIRE)--Closed Loop Medicine Ltd., a leader in AI-enabled precision medicines, today announced the expansion of its US patent portfolio. Strengthening its cardiometabolic treatment portfolio, the Company now has patents covering advancements in GLP-1 therapies for obesity and diabetes, and direct oral anticoagulants (DOACs) for cardiovascular health. Closed Loop Medicine holds over 65 filings across 16 patent families, marking a significant milestone in its mission to deliver p...

Closed Loop Medicine Appoints Luba Greenwood as Chair of the Board of Directors

LONDON--(BUSINESS WIRE)--Closed Loop Medicine Ltd., a leading TechBio company leveraging AI, machine learning, and personalized dosing to enhance drug development, today announced the appointment of Luba Greenwood as Chair of its Board of Directors. Luba is a distinguished executive and investor with over 20 years’ experience in healthcare and tech. She has led over $10 billion USD in deals and investment over multiple therapeutic areas, leading success and scaling companies across the life sci...
Back to Newsroom